11 reports

  • DORMANT PRODUCTS, H1 2018 (CONTD..1), H1 2018
  • PIPELINE BY ONCOVIR INC, H1 2017

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2018 Summary Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms....

  • Pancreatic Cancer
  • Therapy
  • Vaccine
  • Canada
  • Hemispherx Biopharma, Inc.
  • PIPELINE BY ONCOVIR INC, H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017

The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Biopharmaceutical
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • Hemispherx Biopharma, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2017
  • RECOMBINANT PROTEIN TO ANTAGONIZE CXCR4 FOR ONCOLOGY - DRUG PROFILE

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Pipeline Review, H2 Summary According to the recently published report ’C-X-C Chemokine...

  • Pancreatic Cancer
  • Renal Cancer
  • United States
  • Product Initiative
  • BioLineRx Ltd.
  • Non-Hodgkin Lymphoma

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H1 2018 Summary C-X-C Chemokine Receptor Type...

  • Cancer
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • BioLineRx Ltd.
  • DIAGNOSTIC TEST - PANCREATIC CANCER - PRODUCT STATUS
  • DIAGNOSTIC TEST - PANCREATIC CANCER - PRODUCT DESCRIPTION

HIV/ AIDS and other life threatening diseases.

  • Cancer
  • Clinical Trial
  • Pancreatic Cancer
  • United States
  • Proteome Sciences
  • PIPELINE BY BRISTOL-MYERS SQUIBB COMPANY, H2 2016
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2016 (CONTD..1)

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 Summary Global Markets Direct’s, ‘C-X-C Chemokine Receptor Type...

  • Pancreatic Cancer
  • Renal Cancer
  • Research And Development
  • Therapy
  • BioLineRx Ltd.

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Eye Disease
  • Pancreatic Cancer
  • United States
  • Product Initiative
  • Ohr Pharmaceutical Inc.

Its product line includes chemicallysynthesized drugs and biological products in the areas of cancer, psychiatric disorders, cardiovascular disorders, diabetes, hepatitis B, HIV/ AIDS and rheumatoid arthritis.

  • Cancer
  • Pancreatic Cancer
  • Therapy
  • United States
  • Product Initiative
  • 5. All the trials included are unique trials.

Just one week after the U. S.

  • Clinical Trial
  • Drug Discovery And Development
  • Pancreatic Cancer
  • Pharmaceutical
  • World
  • METASTATIC PANCREATIC CANCER - PIPELINE BY BRISTOL-MYERS SQUIBB COMPANY, H1 2016

Metastatic Pancreatic Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Metastatic Pancreatic Cancer - Pipeline Review, H1 2016’, provides an overview of the Metastatic Pancreatic Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for...

  • Chemotherapy
  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative
  • METASTATIC PANCREATIC CANCER - PIPELINE BY BRISTOL-MYERS SQUIBB COMPANY, H2 2016
  • METASTATIC PANCREATIC CANCER - PIPELINE BY GILEAD SCIENCES, INC., H2 2016

Metastatic Pancreatic Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metastatic Pancreatic Cancer - Pipeline Review, H2 2016’, provides an overview of the Metastatic Pancreatic Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for...

  • Cancer
  • Pancreatic Cancer
  • United States
  • Company
  • Product Initiative